Results 311 to 320 of about 974,159 (389)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Trans-Sigmoidal Endoscopic Ultrasound-Guided Fine-Needle Biopsy of Pancreatic Allograft in Simultaneous Pancreas-Kidney Transplant Recipient: A Novel Approach Following Conventional Technique Failure. [PDF]

ACG Case Rep J
Ingawale S, Vantanasiri K, Patel C, Smith M, Jue TL.   +4 more
europepmc   +1 more source

Islet-cell adenoma of the pancreas

, 1959
Merlin Muktiali, W. J. Blignault
openalex   +1 more source

Annular pancreas

Journal of British Surgery, 1953
openaire   +2 more sources

Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells

Advanced Science, EarlyView.
This study demonstrates that tumor‐derived IL‐35 promotes pancreatic cancer fibrosis by indirectly activating pancreatic stellate cells through IGFBP2/IGF‐1R/PI3K‐Akt and Tsp‐1/TGF‐β pathways. IL‐35 blockade reduces stromal fibrosis, restores chemosensitivity, and synergizes with gemcitabine‐based regimens, highlighting IL‐35 as a promising therapeutic
Hui Li, Huizhi Sun, Jing Liu, Yan Wu, Lin Wei, Jianming Li, Yudong Yuan, Peng Xie, Chao Xu, Guolu Luo, Yuqi Guan, Yukuan Feng, Antao Chang, Jihui Hao, Chongbiao Huang   +14 more
wiley   +1 more source

Lactococcus lactis-HSP65 requires TLR2 to induce tolerogenic dendritic cells and confer protection against type 1 diabetes in a murine model. [PDF]

Cell Mol Life Sci
Elias-Oliveira J, Rodrigues VF, Pereira ÍS, Barbosa SC, Pereira JA, Pacheco TCF, Machado MSG, Masson AP, Rios WM, Gardinassi LG, Miyoshi A, Azevedo V, Silva CL, Tostes RC, Carlos D.   +14 more
europepmc   +1 more source

Effect of Different Doses of Sea Buckthorn (Hippophae rhamnoides L.) Seed Extract (Oil) on Histology of Islets of Langerhan of Pancreas in Alloxan Induced Diabetic Male Wistar Rats

Shagufta Nasreen
openalex   +2 more sources

Clinofibrate Disrupts the SNORA80B/YTHDC1‐Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC

Advanced Science, EarlyView.
This study uncovers a non‐canonical role of SNORA80B in ESCC, showing it mediates AR‐driven metabolic reprogramming via N⁶‐methyladenosine (m6A) methylation. By binding YTHDC1, SNORA80B stabilizes cholesterol‐metabolic enzyme mRNAs and promotes tumor progression. The FDA‐approved drug clinofibrate inhibits SNORA80B by disrupting cholesterol homeostasis,
Hongyu Yuan, Ge Ge, LiQiu Liu, Sijun Hu, Miaomiao Tian, Yongzhan Nie, Zitong Zhao, Yongmei Song   +7 more
wiley   +1 more source

Two Ducts, One Drug-Pembrolizumab-Induced Pancreatic Injury Manifesting as Double-Duct Sign. [PDF]

ACG Case Rep J
Alsaleh T, Almujarkesh MK, Abbasi A, Arain M, George J.   +4 more
europepmc   +1 more source

Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles

Advanced Science, EarlyView.
This study presents heparin‐derived nanoparticles (HP‐NPs) as a novel precision medicine platform that combines therapeutic and delivery functions. HP‐NPs target drug‐resistant glioblastoma stem cells, reprogramming them into a drug‐sensitive phenotype and significantly reducing tumor progression.
Vadim Le Joncour, Austin D. Evans, Camilla Karoliina Bergström, Vignesh Kumar Rangasami, Sumanta Samanta, Nithiyanandan Krishnan, Yuji Teramura, Bo Nilsson, Patricia Hedenqvist, Elin Manell, Jons Hilborn, Marianne‐Jensen Waern, Oommen P. Varghese, Pirjo Laakkonen, Oommen P. Oommen   +14 more
wiley   +1 more source